Y-mAbs Therapeutics Inc (NAS:YMAB)
$ 12.73 0.71 (5.91%) Market Cap: 558.63 Mil Enterprise Value: 452.90 Mil PE Ratio: 0 PB Ratio: 5.63 GF Score: 56/100

Q4 2019 Y-mAbs Therapeutics, Inc Earnings Call Transcript

Mar 12, 2020 / 08:30PM GMT
Release Date Price: $19.66 (-14.45%)
Operator

Greetings, and welcome to the Y-mAbs' Full Year 2019 Earnings Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Thomas Gad, Chairman and President. Please go ahead.

Thomas Gad
Y-mAbs Therapeutics, Inc. - Founder, Chairman, President & Head of Business Development and Strategy

Thank you, Ashley. Good afternoon, everyone, and thank you for joining us on this particular day. So 2019 was the year that we believe we made significant progress on our strategy and took steps that positioned us very well for 2020, as we worked to complete 2 BLA submissions and prepare for 2 potential product launches while significantly expanding our clinical activities.

We ended 2019 with $207 million in cash. And as you know, in late October, we completed a secondary offering led by Morgan Stanley, JPMorgan and BAML, in which we raised approximately net proceeds of $135 million to the company. These proceeds have further strengthened our balance sheet for the potential launch

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot